PubRank

J L Rouleau

Author PubWeight™ 163.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 23.76
2 Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011 7.62
3 Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 7.05
4 Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999 3.26
5 Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997 3.13
6 Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994 2.74
7 Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med 1992 2.72
8 N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994 2.05
9 Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997 2.01
10 Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 1997 1.96
11 Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001 1.93
12 Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000 1.88
13 Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999 1.76
14 Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998 1.67
15 Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994 1.67
16 Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990 1.66
17 Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998 1.63
18 Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation 1982 1.54
19 Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998 1.52
20 Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest 1989 1.52
21 The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003 1.49
22 Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 1998 1.45
23 Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001 1.39
24 Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997 1.33
25 Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation 1995 1.26
26 Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001 1.23
27 Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ Res 1991 1.22
28 Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001 1.21
29 Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986 1.16
30 Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997 1.14
31 Assessment of psychosocial functioning of patients with sickle cell disease. South Med J 1988 1.12
32 Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J 2001 1.09
33 Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997 1.08
34 Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000 1.06
35 The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 2000 1.04
36 Age and gender differences in excitation-contraction coupling of the rat ventricle. J Physiol 1998 1.04
37 Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Am J Cardiol 1997 1.04
38 Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J 2000 1.02
39 Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997 1.02
40 Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997 1.01
41 Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. J Am Coll Cardiol 1983 1.01
42 Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999 1.01
43 Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 1985 0.99
44 Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med 1988 0.99
45 Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999 0.96
46 Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure. J Am Coll Cardiol 1991 0.96
47 Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Circulation 1986 0.96
48 Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1994 0.96
49 Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 1984 0.96
50 Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. Am Heart J 1988 0.95
51 Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992 0.94
52 Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J 2003 0.92
53 Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. Circ Res 1991 0.90
54 Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure. Br Heart J 1982 0.89
55 Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol 1994 0.89
56 Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995 0.89
57 Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989 0.89
58 Faster time to peak tension and velocity of shortening in right versus left ventricular trabeculae and papillary muscles of dogs. Circ Res 1986 0.88
59 A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. J Card Fail 2001 0.88
60 Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation 1999 0.86
61 Age- and gender-related changes in endothelin and catecholamine release, and in autonomic balance in response to head-up tilt. Clin Sci (Lond) 1997 0.85
62 The importance of microalbuminuria as a cardiovascular risk indicator: A review. Can J Cardiol 2002 0.85
63 Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998 0.85
64 Prazosin and congestive heart failure: short- and long-term therapy. Am J Med 1981 0.84
65 Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. Am Heart J 1982 0.84
66 The hospital course and short term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1993 0.84
67 Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol 1987 0.83
68 Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the Syrian hamster. Circ Res 1982 0.83
69 Multiple paraphilic diagnoses among sex offenders. Bull Am Acad Psychiatry Law 1988 0.83
70 Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. Circulation 1998 0.83
71 Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction. Am Heart J 2001 0.82
72 Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001 0.82
73 Functional and morphological characteristics of compensated and decompensated cardiac hypertrophy in dogs with chronic infrarenal aorto-caval fistulas. Circ Res 1990 0.82
74 Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure. Am Heart J 1990 0.82
75 Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure. Am Heart J 1985 0.82
76 Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. Br Heart J 1986 0.81
77 Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ Res 1993 0.81
78 The cardiac endothelium: functional morphology, development, and physiology. Prog Cardiovasc Dis 1997 0.81
79 Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol 1999 0.81
80 The effect of captopril on the coronary circulation and myocardial metabolism of patients with coronary artery disease. Postgrad Med J 1986 0.81
81 Acute effects of captopril on the coronary circulation of patients with hypertension and angina. Am J Med 1984 0.81
82 Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 2001 0.81
83 Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999 0.81
84 Increased preproenkephalin A gene expression in the rat heart after induction of a myocardial infarction. Biochem Cell Biol 1992 0.81
85 Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand. Circulation 1983 0.80
86 Vascular endothelial dysfunction contributes to myocardial depression in ischemia-reperfusion in the rat. Can J Physiol Pharmacol 1998 0.80
87 How to digitalize and to maintain optimal digoxin levels in congestive heart failure. Cardiovasc Drugs Ther 1989 0.80
88 Effects of taurine depletion on intrinsic contractility of rat ventricular papillary muscles. Can J Physiol Pharmacol 1990 0.79
89 LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol 2000 0.79
90 A new apex-ejecting perfused rat heart preparation: relation between coronary flow and loading conditions. Cardiovasc Res 1983 0.79
91 Sodium and water excretion abnormalities in congestive heart failure. Determinant factors and clinical implications. Ann Intern Med 1986 0.79
92 Metaiodobenzylguanidine [131I] scintigraphy detects impaired myocardial sympathetic neuronal transport function of canine mechanical-overload heart failure. Circ Res 1987 0.79
93 Altered protein kinase C regulation of phosphoinositide-coupled receptors in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994 0.78
94 Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovasc Res 1990 0.78
95 Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995 0.78
96 Myocardial catecholamine balance during angina: effects of calcium entry blockers, verapamil and nifedipine. Am Heart J 1985 0.78
97 Vasodilators in heart failure secondary to coronary artery disease. Am Heart J 1982 0.78
98 Vasodilator and inotropic effects of the antiarrhythmic drug melperone. J Cardiovasc Pharmacol 1982 0.78
99 Captopril does not prevent nitroglycerin tolerance in heart failure. Can J Cardiol 1990 0.78
100 Tension-frequency relationships in normal and cardiomyopathic dog and hamster myocardium. J Mol Cell Cardiol 1995 0.78
101 Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction. Peptides 2001 0.78
102 Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther 2000 0.78
103 The antiarrhythmic effect of the ACE inhibitor captopril in patients with congestive heart failure largely is due to its potassium sparing effects. Can J Cardiol 1992 0.77
104 Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol 2001 0.77
105 Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J 2000 0.77
106 Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J Cardiovasc Pharmacol 1998 0.77
107 Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Am Heart J 1998 0.77
108 Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J Mol Cell Cardiol 1991 0.77
109 Endocardial endothelium and myocardial performance in rats: effects of changing extracellular calcium and phenylephrine. J Mol Cell Cardiol 1996 0.76
110 Verapamil, propranolol, and hydralazine protect against the acute cardiac depression induced by adriamycin. Cardiovasc Res 1983 0.76
111 Captopril - an oral angiotensin-converting enzyme inhibitor in CHF. Acta Med Scand Suppl 1981 0.76
112 Myocardial beta-adrenergic and mechanical properties in pacing-induced heart failure in dogs. Am J Physiol 1992 0.76
113 Alpha 1-adrenergic stimulation increases the Vmax of isolated myocardial papillary muscles. Can J Physiol Pharmacol 1991 0.76
114 Impaired endothelin-1 release in tilt-induced syncope. Am J Cardiol 1998 0.76
115 Vasopeptidase inhibitors: potential role in the treatment of heart failure. Heart Fail Monit 2001 0.76
116 Myocardial alpha1-adrenoceptor: inotropic effect and physiologic and pathologic implications. Life Sci 1997 0.76
117 Kinetics of pulmonary uptake of serotonin during exercise in dogs. J Appl Physiol (1985) 1996 0.76
118 Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem 1998 0.76
119 Vasopressin in congestive heart failure. J Cardiovasc Pharmacol 1986 0.76
120 Regulation of the endothelin-1 transmembrane signaling pathway: the potential role of agonist-induced desensitization in the coronary artery of the rapid ventricular pacing-overdrive dog model of heart failure. J Mol Cell Cardiol 1993 0.75
121 Hypercalcemic cardiomyopathy associated with primary hyperparathyroidism mimicking primary obstructive hypertrophic cardiomyopathy. Can J Cardiol 1998 0.75
122 Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction. Can J Physiol Pharmacol 1998 0.75
123 Pulmonary angiotensin-converting enzyme substrate hydrolysis during exercise. J Appl Physiol (1985) 1992 0.75
124 Alterations in angina threshold with nifedipine during pacing induced angina. Br Heart J 1984 0.75
125 Use of norepinephrine uptake to measure lung capillary recruitment with exercise. J Appl Physiol (1985) 1990 0.75
126 Medical treatment of heart failure: the Canadian Cardiovascular Society's Consensus Conference revisited. Cardiovasc Drugs Ther 1997 0.75
127 Age-dependent changes in the effects of endocardial endothelium on the contractile characteristics of its adjacent myocardium in rats. J Mol Cell Cardiol 1997 0.75
128 Endocardial function in pacing-induced heart failure in the dog. J Mol Cell Cardiol 1993 0.75
129 Role of endothelial cells in cardiovascular function. Life Sci 1994 0.75
130 Sexual abuses. Psychiatr Clin North Am 1995 0.75
131 Women's role in male sexual dysfunction. Acta Urol Belg 1989 0.75
132 A pragmatic approach to the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction. Can J Cardiol 1996 0.75
133 [The role of beta-2 stimulators in cardiac insufficiency]. Ann Cardiol Angeiol (Paris) 1984 0.75
134 Lack of relation between the ventricular refractory period prolongation by amiodarone and the thyroid state in rats. J Pharmacol Exp Ther 1987 0.75
135 Age related changes in contractility and alpha 1 adrenergic responsiveness of myocardium from normal hamsters and hamsters with hereditary cardiomyopathy. Cardiovasc Res 1993 0.75
136 Medical management of patients with angina. Has first-line management changed? JAMA 1984 0.75
137 Predicting child molesters' response to treatment. Ann N Y Acad Sci 1988 0.75
138 Sexotherapy and disorders of ejaculation. Acta Urol Belg 1989 0.75
139 Vasodilator therapy in chronic congestive heart failure. Am J Cardiol 1988 0.75
140 The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. Am Heart J 2001 0.75
141 Papillary muscle rupture complicating an acute myocardial infarction. Can J Cardiol 2001 0.75
142 Vascular-derived myocardial contractile factor: positive myocardial inotropic substance released from medial layer of the canine aorta. J Mol Cell Cardiol 1996 0.75
143 Beta-adrenergic responsiveness of papillary muscles in the rat postinfarction model. Can J Physiol Pharmacol 1996 0.75
144 Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998 0.75
145 Altered responsiveness to endothelin-1 of myocardium from pacing-induced heart failure model in the dog. Cardiovasc Drugs Ther 1996 0.75
146 Hemodynamic and metabolic effects of vasodilators, nitrates, hydralazine, prazosin and captopril in chronic ischemic heart failure. Acta Med Scand Suppl 1981 0.75
147 Direct pharmacologic and osmolal effects of contrast media on the mechanics of heart muscle isolated from cats. Am Heart J 1984 0.75
148 Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995 0.75
149 Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study. Angiology 1996 0.75
150 Effects of ryanodine on cat papillary muscle and isolated rat heart. Am Heart J 1985 0.75
151 Physiologic methods of diagnosing organic impotence in diabetic males and diabetic females. Acta Urol Belg 1988 0.75
152 Beta-adrenergic signal transduction and contractility in the canine heart after cardiopulmonary bypass. Cardiovasc Res 1997 0.75
153 Paradoxical decrease in circulating neuropeptide Y-like immunoreactivity during mild orthostatic stress in subjects with and without congestive heart failure. Eur Heart J 1993 0.75
154 [Angina: beware of apparent benignity]. Union Med Can 1992 0.75
155 Diastolic dysfunction. Can J Cardiol 1996 0.75
156 Protein synthesis is increased in heart failure induced by low dose adriamycin in rabbits. Can J Physiol Pharmacol 1989 0.75
157 Myocardial contractile responsiveness to endothelin-1 in the post-infarction rat model of heart failure: effects of chronic quinapril. J Mol Cell Cardiol 2001 0.75
158 Hydralazine in chronic CHF. Acta Med Scand Suppl 1981 0.75
159 Overview of clinical trials in congestive heart failure. Can J Cardiol 1993 0.75